Literature DB >> 24982089

Maternal intravenous treatment with either azithromycin or solithromycin clears Ureaplasma parvum from the amniotic fluid in an ovine model of intrauterine infection.

Yuichiro Miura1, Matthew S Payne1, Jeffrey A Keelan1, Andres Noe1, Sean Carter1, Rory Watts1, Owen B Spiller2, Alan H Jobe3, Suhas G Kallapur3, Masatoshi Saito4, Sarah J Stock5, John P Newnham1, Matthew W Kemp6.   

Abstract

Intrauterine infection with Ureaplasma spp. is strongly associated with preterm birth and adverse neonatal outcomes. We assessed whether combined intraamniotic (IA) and maternal intravenous (IV) treatment with one of two candidate antibiotics, azithromycin (AZ) or solithromycin (SOLI), would eradicate intrauterine Ureaplasma parvum infection in a sheep model of pregnancy. Sheep with singleton pregnancies received an IA injection of U. parvum serovar 3 at 85 days of gestational age (GA). At 120 days of GA, animals (n=5 to 8/group) received one of the following treatments: (i) maternal IV SOLI with a single IA injection of vehicle (IV SOLI only); (ii) maternal IV SOLI with a single IA injection of SOLI (IV+IA SOLI); (iii) maternal IV AZ and a single IA injection of vehicle (IV AZ only); (iv) maternal IV AZ and a single IA injection of AZ (IV+IA AZ); or (v) maternal IV and single IA injection of vehicle (control). Lambs were surgically delivered at 125 days of GA. Treatment efficacies were assessed by U. parvum culture, quantitative PCR, enzyme-linked immunosorbent assay, and histopathology. Amniotic fluid (AF) from all control animals contained culturable U. parvum. AF, lung, and chorioamnion from all AZ- or SOLI-treated animals (IV only or IV plus IA) were negative for culturable U. parvum. Relative to the results for the control, the levels of expression of interleukin 1β (IL-1β), IL-6, IL-8, and monocyte chemoattractant protein 2 (MCP-2) in fetal skin were significantly decreased in the IV SOLI-only group, the MCP-1 protein concentration in the amniotic fluid was significantly increased in the IV+IA SOLI group, and there was no significant difference in the histological inflammation scoring of lung or chorioamnion among the five groups. In the present study, treatment with either AZ or SOLI (IV only or IV+IA) effectively eradicated macrolide-sensitive U. parvum from the AF. There was no discernible difference in antibiotic therapy efficacy between IV-only and IV+IA treatment regimens relative to the results for the control.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24982089      PMCID: PMC4135857          DOI: 10.1128/AAC.03187-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  53 in total

1.  Azithromycin and the risk of cardiovascular death.

Authors:  Wayne A Ray; Katherine T Murray; Kathi Hall; Patrick G Arbogast; C Michael Stein
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

2.  The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments.

Authors:  Stephen A Bustin; Vladimir Benes; Jeremy A Garson; Jan Hellemans; Jim Huggett; Mikael Kubista; Reinhold Mueller; Tania Nolan; Michael W Pfaffl; Gregory L Shipley; Jo Vandesompele; Carl T Wittwer
Journal:  Clin Chem       Date:  2009-02-26       Impact factor: 8.327

Review 3.  Antibiotics in the clinical pipeline in 2013.

Authors:  Mark S Butler; Mark A Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2013-09-04       Impact factor: 2.649

4.  National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications.

Authors:  Hannah Blencowe; Simon Cousens; Mikkel Z Oestergaard; Doris Chou; Ann-Beth Moller; Rajesh Narwal; Alma Adler; Claudia Vera Garcia; Sarah Rohde; Lale Say; Joy E Lawn
Journal:  Lancet       Date:  2012-06-09       Impact factor: 79.321

Review 5.  Antibiotics for treating bacterial vaginosis in pregnancy.

Authors:  Peter Brocklehurst; Adrienne Gordon; Emer Heatley; Stephen J Milan
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

6.  Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance.

Authors:  Michael L Beeton; Victoria J Chalker; Nicola C Maxwell; Sailesh Kotecha; O Brad Spiller
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

Review 7.  Ureaplasma species: role in neonatal morbidities and outcomes.

Authors:  Rose Marie Viscardi
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2013-08-19       Impact factor: 5.747

8.  In-vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against Mycoplasma hominis and Ureaplasma ssp. isolated in Germany over 20 years.

Authors:  R Krausse; S Schubert
Journal:  Clin Microbiol Infect       Date:  2010-11       Impact factor: 8.067

9.  Maternal azithromycin therapy for Ureaplasma intraamniotic infection delays preterm delivery and reduces fetal lung injury in a primate model.

Authors:  Peta L Grigsby; Miles J Novy; Drew W Sadowsky; Terry K Morgan; Mary Long; Ed Acosta; Lynn B Duffy; Ken B Waites
Journal:  Am J Obstet Gynecol       Date:  2012-10-23       Impact factor: 8.661

Review 10.  Epidemiology and causes of preterm birth.

Authors:  Robert L Goldenberg; Jennifer F Culhane; Jay D Iams; Roberto Romero
Journal:  Lancet       Date:  2008-01-05       Impact factor: 79.321

View more
  15 in total

Review 1.  The Human Ureaplasma Species as Causative Agents of Chorioamnionitis.

Authors:  Emma L Sweeney; Samantha J Dando; Suhas G Kallapur; Christine L Knox
Journal:  Clin Microbiol Rev       Date:  2016-12-14       Impact factor: 26.132

2.  The Paradoxical Effects of Chronic Intra-Amniotic Ureaplasma parvum Exposure on Ovine Fetal Brain Development.

Authors:  Ruth Gussenhoven; Daan R M G Ophelders; Matthew W Kemp; Matthew S Payne; Owen B Spiller; Michael L Beeton; Sarah J Stock; Bertha Cillero-Pastor; Florian P Y Barré; Ron M A Heeren; Lilian Kessels; Bas Stevens; Bart P Rutten; Suhas G Kallapur; Alan H Jobe; Boris W Kramer; Tim G A M Wolfs
Journal:  Dev Neurosci       Date:  2017-08-29       Impact factor: 2.984

Review 3.  Antenatal prevention of cerebral palsy and childhood disability: is the impossible possible?

Authors:  Stacey J Ellery; Meredith Kelleher; Peta Grigsby; Irina Burd; Jan B Derks; Jon Hirst; Suzanne L Miller; Larry S Sherman; Mary Tolcos; David W Walker
Journal:  J Physiol       Date:  2018-07-21       Impact factor: 5.182

4.  Clarithromycin prevents preterm birth and neonatal mortality by dampening alarmin-induced maternal-fetal inflammation in mice.

Authors:  Jose Galaz; Roberto Romero; Marcia Arenas-Hernandez; Marcelo Farias-Jofre; Kenichiro Motomura; Zhenjie Liu; Naoki Kawahara; Catherine Demery-Poulos; Tzu Ning Liu; Justin Padron; Bogdan Panaitescu; Nardhy Gomez-Lopez
Journal:  BMC Pregnancy Childbirth       Date:  2022-06-20       Impact factor: 3.105

Review 5.  Role of Ureaplasma Respiratory Tract Colonization in Bronchopulmonary Dysplasia Pathogenesis: Current Concepts and Update.

Authors:  Rose Marie Viscardi; Suhas G Kallapur
Journal:  Clin Perinatol       Date:  2015-10-09       Impact factor: 3.430

6.  A new antibiotic regimen treats and prevents intra-amniotic inflammation/infection in patients with preterm PROM.

Authors:  JoonHo Lee; Roberto Romero; Sun Min Kim; Piya Chaemsaithong; Bo Hyun Yoon
Journal:  J Matern Fetal Neonatal Med       Date:  2015-12-02

7.  Association between maternal cervicovaginal swab positivity for Ureaplasma spp. or other microorganisms and neonatal respiratory outcome and mortality.

Authors:  Karen Van Mechelen; Marisse Meeus; Veerle Matheeussen; Gilbert Donders; Yves Jacquemyn; Ludo Mahieu
Journal:  J Perinatol       Date:  2020-09-09       Impact factor: 3.225

Review 8.  Preterm birth, intrauterine infection, and fetal inflammation.

Authors:  Matthew W Kemp
Journal:  Front Immunol       Date:  2014-12-01       Impact factor: 7.561

Review 9.  Advances in the Prevention of Infection-Related Preterm Birth.

Authors:  Ronald F Lamont
Journal:  Front Immunol       Date:  2015-11-16       Impact factor: 7.561

Review 10.  A New, Potent, and Placenta-Permeable Macrolide Antibiotic, Solithromycin, for the Prevention and Treatment of Bacterial Infections in Pregnancy.

Authors:  Jeffrey A Keelan; Matthew S Payne; Matthew W Kemp; Demelza J Ireland; John P Newnham
Journal:  Front Immunol       Date:  2016-04-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.